Access the full text.
Sign up today, get DeepDyve free for 14 days.
F. Alfonso, Maria Pérez-Vizcayno, Alberto Cárdenas, B. Garcia, Del Blanco, B. Seidelberger, A. Íñiguez, M. Gómez-Recio, M. Masotti, M. Velázquez, J. Sanchis, A. García-Touchard, J. Zueco, A. Bethencourt, R. Melgares, Á. Cequier, Antonio Domínguez, V. Mainar, J. López-Mínguez, J. Moreu, V. Martí, R. Moreno, P. Jiménez-Quevedo, N. Gonzalo, C. Fernández, C. Macaya (2014)
A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent).Journal of the American College of Cardiology, 63 14
R. Byrne, F. Neumann, J. Mehilli, S. Pinieck, Britta Wolff, K. Tiroch, S. Schulz, M. Fusaro, I. Ott, T. Ibrahim, J. Hausleiter, C. Valina, J. Pache, K. Laugwitz, S. Massberg, A. Kastrati (2013)
Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trialThe Lancet, 381
B. Scheller, Y. Clever, B. Kelsch, C. Hehrlein, W. Bocksch, W. Rutsch, D. Haghi, U. Dietz, U. Speck, M. Böhm, B. Cremers (2012)
Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter.JACC. Cardiovascular interventions, 5 3
B. Scheller, U. Speck, B. Romeike, Alexander Schmitt, M. Sovák, M. Böhm, H. Stoll (2003)
Contrast media as carriers for local drug delivery. Successful inhibition of neointimal proliferation in the porcine coronary stent model.European heart journal, 24 15
L. Pastormerlo, M. Ciardetti, G. Trianni, M. Ravani, Mathis Shlueter, M. Vaghetti, M. Coceani, A. Rizza, S. Berti, C. Palmieri (2014)
Drug eluting balloon: a multipurpose tool for coronary revascularization with optimal long-term follow-up results.Journal of interventional cardiology, 27 6
Drug‐coated balloon (DCB) technology emerged over a decade ago as a remedy to restenosis. The technology developed after the introduction of drug‐eluting stents (DES) with the motivation to overcome the limitations and shortcomings of DES—primarily stent thrombosis, the need for prolonged dual antiplatelet therapy (DAPT), and difficulty to deliver the stents into small vessels or torturous vessels. Initially, DCBs were targeted for the treatment of bare metal stents (BMS). The DCB technology incorporated a paclitaxel drug with an antiproliferative mechanism loaded on an angioplasty balloon, using an excipient to enhance the solubility and the bioavailability of the paclitaxel and to improve the release of the drug into the vessel wall and to the adventitia. Unlike DES that elute the drug over several months, DCBs do not elute the drug. Rather, DCBs release the drug rapidly primarily during the inflation/deflation of the balloon, and therefore they should be named DCBs and not drug‐eluting balloons—as many authors wrongly call them, including Pastormerlo et al. who published an article on the technology in this issues of the journal. DCB technology developed simultaneously both for the coronary and for the peripheral indications. This editorial will be limited to the coronary indications. Early
Journal of Interventional Cardiology – Wiley
Published: Dec 1, 2014
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.